Mangrove Partners Mereo Biopharma Group PLC Transaction History
Mangrove Partners
- $778 Million
- Q3 2025
A detailed history of Mangrove Partners transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Mangrove Partners holds 7,790,580 shares of MREO stock, worth $14.2 Million. This represents 1.99% of its overall portfolio holdings.
Number of Shares
7,790,580
Previous 8,636,485
9.79%
Holding current value
$14.2 Million
Previous $23.4 Million
33.76%
% of portfolio
1.99%
Previous 3.39%
Shares
5 transactions
Others Institutions Holding MREO
# of Institutions
96Shares Held
99.9MCall Options Held
2.23MPut Options Held
179K-
Janus Henderson Group PLC London, X016.3MShares$29.6 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$27.9 Million0.5% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.44MShares$17.2 Million0.79% of portfolio
-
Abrdn PLC5.54MShares$10.1 Million0.02% of portfolio
-
683 Capital Management, LLC New York, NY4.88MShares$8.87 Million0.57% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $227M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...